TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- Will Trial Lawyers and the Ontario Health Coalition invite members of the media to attend a press conference regarding patient safety issues related to Grifols, one of the world's largest manufacturers of plasma-derived medical products. The media conference will examine issues surrounding public safety and reported adverse events; patients’ legal rights and available supports; regulatory oversight, transparency, and accountability. Speakers will disc

NEW YORK, July 13, 2026 /PRNewswire/ -- Six years after a Times Square billboard inspired an extraordinary chain of events in an international news story that ultimately saved the life of Television News Producer Marc Weiner, he and Retired NYPD Detective Michael Lollo are joining forces to help another father in kidney failure in an effort to repeat history. Continue Reading "If this billboard inspires more people to consider living kidney donation, countless families could be saved." Post thi

Milestone reinforces Curaleaf's leadership in bringing pharmaceutical-grade cannabis products to emerging international markets STAMFORD, Conn., July 13, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced that the Spanish Agency of Medicines and Medical Devices ("AEMPS") has formally approved the registration of two standardized cannabis preparations (THC-dominant a

DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recurring revenue growth for Dario Dario IQ's AI-driven personalization increases member engagement by 40% and improves member retention by 20% by leveraging 13+ billion proprietary real-world healthcare data points NEW YORK, July 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the man

DUBLIN, July 13, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe autoimmune diseases. Sponsored by Keenova, the retrospective, physician-reported, survey-based medical chart review study covered in the manuscript used real‑world clinical data to evaluate patient characteristics, treatment patterns, and physicians' assessments of outcomes among individuals with rheu

Fully rechargeable: First fully rechargeable active bone conduction sound processor, with up to 30 hours of battery life on a single charge. †,7-9 Improved power and sound quality: Improved clarity and sound quality, enhanced by the new signal processing platform and powerful lithium-ion battery. Now with fitting range up to 65 dB HL bone conduction thresholds in the mid to high frequencies.¥, 10 A range of streaming options: Joins Cochlear's industry-leading connectivity with streaming from A

The program is designed to enable Pulsenmore to develop and clinically validate AI applications that improve clinical workflow efficiency and enhance the scalability of the company's home ultrasound platform. RAMAT GAN, Israel, July 13, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in connected home ultrasound technology, today announced that it has been selected to participate in Israel's Healthcare AI Regulatory Sandbox Program, established by the Israel Innovat

UC San Diego Health surgeons and wildlife health experts at the San Diego Zoo Safari Park team up to perform the world's first reported mastoidectomy on a gorilla SAN DIEGO, July 13, 2026 /PRNewswire/ -- Mizani, a 12-year-old male western lowland gorilla at the San Diego Zoo Safari Park, underwent a first-of-its-kind mastoidectomy to treat an infection that had spread into portions of his skull. The surgery was performed by a multidisciplinary team of wildlife health experts from the San Diego Z

Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has

Collaboration intended to support broader awareness of NetraMark's clinical development initiatives and NetraAI platformTORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced it has engaged AM Public Relations (AM PR), a healthcare-focused public relations agenc